Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Dual targeting non-overlapping epitopes in HER2 domain IV substantially enhanced HER2/HER2 homodimers and HER2/EGFR heterodimers internalization leading to potent antitumor activity in HER2-positive human gastric cancer ; volume:22 ; number:1 ; day:9 ; month:7 ; year:2024 ; pages:1-15 ; date:12.2024
Journal of translational medicine ; 22, Heft 1 (9.7.2024), 1-15, 12.2024
- Creator
-
Wei, Ruicheng
Zhang, Wenli
Yang, Futang
Li, Qianhao
Wang, Qingyu
Liu, Ningshu
Zhu, Jun
Shan, Yongqiang
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12967-024-05453-8
- URN
-
urn:nbn:de:101:1-2409262102318.612922736708
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 15.08.2025, 7:34 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Wei, Ruicheng
- Zhang, Wenli
- Yang, Futang
- Li, Qianhao
- Wang, Qingyu
- Liu, Ningshu
- Zhu, Jun
- Shan, Yongqiang
- SpringerLink (Online service)
Other Objects (12)
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion
HER2 copy number as predictor of disease-free survival in HER2-positive resectable gastric adenocarcinoma
Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
Endophilin A2 promotes HER2 internalization and sensitivity to trastuzumab-based therapy in HER2-positive breast cancers
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry
Differential response of HER2-positive breast cancer to anti-HER2 therapy based on HER2 protein expression level
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Depicting Biomarkers for HER2-Inhibitor Resistance: Implication for Therapy in HER2-Positive Breast Cancer
TRAF4 hyperactivates HER2 signaling and contributes to Trastuzumab resistance in HER2-positive breast cancer
Das HER2-positive metastasierte Mammakarzinom – aktuelle Behandlungskonzepte
PYK2 promotes HER2-positive breast cancer invasion